Hernix- 40mg(neratinib)
Description
Niratinib is an oral, irreversible tyrosine kinase inhibitor. It is the only product in the world approved for intensive adjuvant therapy after treatment with HER2-positive breast cancer with trastuzumab (Herceptin) to reduce the risk of recurrence. The applicable population is to complete the standard trastuzumab adjuvant treatment of patients with undeveloped disease but high risk factors.
Indications Neratinib:
Breast cancer for women patients completed standard trastuzumab (Herceptin, Herceptin) adjuvant therapy, disease progression, but high-risk factors
Pharmacology Neratinib:
Neratinib is a kinase inhibitor that irreversibly binds to Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), and HER4. Hernix reduces EGFR and HER2 autophosphorylation, downstream MAPK, and AKT signaling pathways. Therefore show antitumor activity in EGFR and/or HER2 expressing carcinoma cell lines. Neratinib human metabolites M3, M6, M7, and M11 inhibited the activity of EGFR, HER2, and HER4 in vitro. In vivo, oral administration of Hernix inhibited tumor growth in mouse xenograft models with tumor cell lines expressing HER2 and EGFR.
Reviews
There are no reviews yet.